Discovery of novel therapeutics through

the targetting of key enzymes in the kynurenine pathway

KyNexis Approach

Targeted Therapies

Leverage Experience in Drug Discovery & Development

Dedicated Translational Medicine Network

Kynurenine pathway

Initial KyNexis programs aimed at regulating Kynurenic acid levels in the brain to improve cognition


Robert SCHWARCZ, Ph.D.

Chief Scientist

Professor of Psychiatry, Pharmacology and Pediatrics,  U. of Maryland School od Medicine, Baltimore, USA and Professor of Pharmacology, Karolinska Institutet,Stockholm,Sweden

Christer KÖHLER, Ph.D.

Chairman of the Board

Former VP and Head of CNS & Pain R&D, AstraZeneca and Global Head, CNS Discovery, Hoffman La-Roche

Johannes LINDE

Chief of Legal and BD

Former Deputy General Counsel, Global R&D, AstraZeneca

Johan LUND, M.D., Ph.D.


Former VP and Global Head of Immunology & Inflammation R&D in Celgene, Pfizer and CNS VP, AstraZeneca

Translational Medicine Network

Dr. Carol TAMMINGA, M.D./Ph.D.

Chair, KyNexis Clinical Advisory Board

Chair in Brain Science and Chief of the Translational Neuroscience Division in Schizophrenia, UT Southwestern Medical Center in Dallas, Lou and Ellen McGinley Distinguished Chair in Psychiatric Research

Dr. Tamminga leads the B-SNIP (Bipolar and Schizophrenia Network for Intermediate Phenotypes) Consortium with 6 collaborating sites in the US which has Has established biologically distinct groups of psychosis patients based on factors such as brain waves, cognitive ability, and damage to brain tissue

About us

We are KyNexis

We discover and develop targeted therapies that make a difference for patients



Office:Riddargatan 16, SE-11451 Stockholm, Sweden